How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?

In patients without relapses in the previous 2 years and in those without Gd+ lesions at baseline, 6-month confirmed disability progression trended towards a reduction with siponimod versus placebo but did not reach statistical significance. 13 Based on the results from EXPAND, siponimod was approved by the European Medicines Agency (EMA) for use in adults with relapses or imaging features of inflammatory activity (i.e., active SPMS). 14 The EXPAND long-term extension study demonstrated that patients with inactive SPMS may pro

also in 111,027 other papers